Advertisement

Topics

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

2019-06-19 03:21:13 | BioPortfolio

Published on BioPortfolio: 2019-06-19T03:21:13-0400

Clinical Trials [481 Associated Clinical Trials listed on BioPortfolio]

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In...

Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

The purpose of this study is to determine if sevelamer carbonate powder is an effective treatment for the control of serum phosphorous levels in patients on dialysis when compared to sevel...

The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4

The aim of this study is to investigate effects of sevelamer carbonate on reducing TMAO in stage 3b-4 CKD (pre-dialysis) patients. The study will also investigate the safety and tolerabili...

A Study of HS219 in Chronic Kidney Disease Patient on Hemodialysis With Hyperphosphatemia

This is a study to evaluate the efficacy and safety of HS219 when given three times a day for 3 weeks to the hemodialysis (HD) patients with hyperphosphatemia whose serum inorganic phospho...

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California

PubMed Articles [678 Associated PubMed Articles listed on BioPortfolio]

A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.

End-stage renal disease is associated with significant comorbidity and mortality. Among its implications, hyperphosphatemia constitutes a consistent and independent risk factor. The use of benchmark t...

Mechanism of Action and Clinical Attributes of Auryxia (Ferric Citrate).

Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, in...

Ferric citrate, nitrate, saponin, and their combinations affect in-vitro ruminal fermentation, production of sulfide and methane, and abundance of select microbial populations.

This study investigated the effects of ferric citrate, nitrate, and saponin, both individually and in combination, on sulfidogenesis, methanogenesis, rumen fermentation, and abundances of select micro...

The Role of Extracellular Phosphate Levels on Kidney Disease Progression in a Podocyte Injury Mouse Model.

Hyperphosphatemia is a major accelerator of complications in chronic kidney disease and dialysis, and phosphate (Pi) binders have been shown to regulate extracellular Pi levels. Research on hyperphosp...

Pathology of Resin-Induced Gastrointestinal Damage: Report of 15 Cases and Review of Literature.

Medication resins such as Kayexalate and Sevelamer used in the setting of chronic kidney disease for the correction of hyperkalemia and hyperphosphatemia are associated with gastrointestinal mucosal i...

Medical and Biotech [MESH] Definitions

A polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease.

A species of gram-positive, aerobic bacteria that causes granulomatous or ulcerating skin lesions in immunosuppressed persons. This organism owes its name to its requirement for growth of high levels of iron, conveniently supplied as blood, heme, or ferric ammonium citrate.

The reaction of potassium ferrocyanide with ferric iron to yield a dark blue precipitate at the sites of the ferric iron. Used to determine ferric iron in tissues, particularly in the diagnosis of disorders of iron metabolism.

An enzyme that, in the presence of ATP and COENZYME A, catalyzes the cleavage of citrate to yield acetyl CoA, oxaloacetate, ADP, and ORTHOPHOSPHATE. This reaction represents an important step in fatty acid biosynthesis. This enzyme was formerly listed as EC 4.1.3.8.

A field of chemistry which pertains to chemical compounds or ions that do not contain the element carbon (with the exception of carbon dioxide and compounds containing a carbonate radical, e.g., calcium carbonate).

More From BioPortfolio on "Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial